Tyler R C, Muramatsu M, Abman S H, Stelzner T J, Rodman D M, Bloch K D, McMurtry I F
Cardiovascular Pulmonary Research Laboratory, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
Am J Physiol. 1999 Feb;276(2):L297-303. doi: 10.1152/ajplung.1999.276.2.L297.
Endothelial nitric oxide (NO) synthase (eNOS) mRNA and protein and NO production are increased in hypoxia-induced hypertensive rat lungs, but it is uncertain whether eNOS gene expression and activity are increased in other forms of rat pulmonary hypertension. To investigate these questions, we measured eNOS mRNA and protein, eNOS immunohistochemical localization, perfusate NO product levels, and NO-mediated suppression of resting vascular tone in chronically hypoxic (3-4 wk at barometric pressure of 410 mmHg), monocrotaline-treated (4 wk after 60 mg/kg), and fawn-hooded (6-9 mo old) rats. eNOS mRNA levels (Northern blot) were greater in hypoxic and monocrotaline-treated lungs (130 and 125% of control lungs, respectively; P < 0.05) but not in fawn-hooded lungs. Western blotting indicated that eNOS protein levels increased to 300 +/- 46% of control levels in hypoxic lungs (P < 0.05) but were decreased by 50 +/- 5 and 60 +/- 11%, respectively, in monocrotaline-treated and fawn-hooded lungs (P < 0.05). Immunostaining showed prominent eNOS expression in small neomuscularized arterioles in all groups, whereas perfusate NO product levels increased in chronically hypoxic lungs (3.4 +/- 1.4 microM; P < 0.05) but not in either monocrotaline-treated (0.7 +/- 0.3 microM) or fawn-hooded (0.45 +/- 0.1 microM) lungs vs. normotensive lungs (0.12 +/- 0.07 microM). All hypertensive lungs had increased baseline perfusion pressure in response to nitro-L-arginine but not to the inducible NOS inhibitor aminoguanidine. These results indicate that even though NO activity suppresses resting vascular tone in pulmonary hypertension, there are differences among the groups regarding eNOS gene expression and NO production. A better understanding of eNOS gene expression and activity in these models may provide insights into the regulation of this vasodilator system in various forms of human pulmonary hypertension.
在低氧诱导的高血压大鼠肺中,内皮型一氧化氮(NO)合酶(eNOS)的mRNA、蛋白及NO生成均增加,但尚不确定在其他形式的大鼠肺动脉高压中eNOS基因表达和活性是否增加。为研究这些问题,我们检测了慢性低氧(在410 mmHg大气压下3 - 4周)、用野百合碱处理(60 mg/kg体重,4周后)及淡色罩帽大鼠(6 - 9月龄)的eNOS mRNA和蛋白、eNOS免疫组化定位、灌注液中NO产物水平以及NO介导的对静息血管张力的抑制作用。低氧和用野百合碱处理的肺中eNOS mRNA水平(Northern印迹法)升高(分别为对照肺的130%和125%;P < 0.05),但淡色罩帽大鼠肺中未升高。蛋白质印迹法显示,低氧肺中eNOS蛋白水平增加至对照水平的300±46%(P < 0.05),而在用野百合碱处理和淡色罩帽大鼠肺中分别降低了50±5%和60±11%(P < 0.05)。免疫染色显示,所有组的小的新肌化小动脉中均有明显的eNOS表达,而慢性低氧肺中灌注液NO产物水平升高(3.4±1.4 μM;P < 0.05),但与正常血压大鼠肺(0.12±0.07 μM)相比,用野百合碱处理的肺(0.7±0.3 μM)和淡色罩帽大鼠肺(0.45±0.1 μM)中均未升高。所有高血压大鼠肺对硝基-L-精氨酸反应时基础灌注压升高,但对诱导型NOS抑制剂氨基胍无反应。这些结果表明,尽管在肺动脉高压中NO活性可抑制静息血管张力,但各组在eNOS基因表达和NO生成方面存在差异。更好地了解这些模型中的eNOS基因表达和活性可能有助于深入了解各种形式的人类肺动脉高压中该血管舒张系统的调节机制。